Automated two-site immunofluorescent assay for the measurement of serum chromogranin A

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 87-91

  Popovici, Théodora ^a   Moreira, Baptiste ^a   Schlageter, Marie Hélène ^a   Bories, Phuong Nhi ^a  

^a Assistance Publique HÔpitaux de Paris ^*  (France)

Author keywords

Automated assay; Chromogranin A; Kryptor; Neuroendocrine tumour

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; METADRENALIN; NORMETADRENALIN; SYNAPTOPHYSIN;

ADRENAL INCIDENTALOMA; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; CUSHING DISEASE; FEMALE; FOLLOW UP; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCAGONOMA; HUMAN; HYPERPARATHYROIDISM; HYPOPHYSIS ADENOMA; IMMUNOFLUORESCENCE TEST; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PARAGANGLIOMA; PERFORMANCE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SMALL INTESTINE TUMOR; THYROID MEDULLARY CARCINOMA; ZOLLINGER ELLISON SYNDROME;

AUTOMATED ASSAY; CGA; CHROMOGRANIN A; ENETS; EUROPEAN NEUROENDOCRINE TUMOR SOCIETY; GASTRO-ENTERO-PANCREATIC; GEP; KRYPTOR; NANETS; NET; NEUROENDOCRINE TUMOUR; NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY; PPI; PROTON PUMP INHIBITORS; UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY; UKINETS;

CHROMOGRANIN A; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEUROENDOCRINE TUMORS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890521183     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.10.029     Document Type: Article

References (18)

1. Deftos L.J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991, 12:181-187.
2. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149.
3. Nobels F.R., Kwekkeboom D.J., Coopmans W., Schoenmakers C.H., Lindemans J., De Herder W.W., et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622-2628.
4. Nobels F.R., Kwekkeboom D.J., Bouillon R., Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998, 28:431-440.
5. Bajetta E., Ferrari L., Martinetti A., Celio L., Procopio G., Artale S., et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999, 86:858-865.
6. Modlin I.M., Oberg K., Chung D.C., Jensen R.T., de Herder W.W., Thakker R.V., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
7. Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010, 17:2427-2443.
8. Ahmed A., Turner G., King B., Jones L., Culliford D., McCance D., et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009, 16:885-894.
9. O'Toole D., Grossman A., Gross D., Delle Fave G., Barkmanova J., O'Connor J., et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009, 90:194-202.
10. Vinik A.I., Woltering E.A., Warner R.R., Caplin M., O'Dorisio T.M., Wiseman G.A., et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010, 39:713-734.
11. Stridsberg M. Measurements of chromogranins and chromogranin-related peptides by immunological methods. Adv Exp Med Biol 2000, 482:319-327.
12. Stridsberg M., Eriksson B., Oberg K., Janson E.T. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003, 177:337-341.
13. Ferrari L., Seregni E., Lucignani G., Bajetta E., Martinetti A., Aliberti G., et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers 2004, 19:295-304.
14. Laslop A., Doblinger A., Weiss U. Proteolytic processing of chromogranins. Adv Exp Med Biol 2000, 482:155-166.
15. Iacangelo A.L., Eiden L.E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995, 58:65-88.
16. Algeciras-Schimnich A., Preissner C.M., Young W.F., Singh R.J., Grebe S.K. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008, 93:91-95.
17. Kimura N., Miura W., Noshiro T., Mizunashi K., Hanew K., Shimizu K., et al. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J 1997, 44:319-327.
18. d'Herbomez M., Forzy G., Bauters C., Tierny C., Pigny P., Carnaille B., et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007, 156:569-575.